Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 1 1

Status

Unknown 2Terminated 2Completed 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Endocrine 5Head & Neck 4Genitourinary 3Lymphoid 2Dermatologic 2Tumor-Agnostic 1Sarcoma 1Other 1Gastrointestinal 1CNS 1Breast 1

Conditions

Thyroid Cancer, Papillary 2Pituitary Neoplasms 2Adenocarcinoma, Follicular 2Thyroid Neoplasms 1Pituitary ACTH Hypersecretion 1Head and Neck Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Everolimus 59lutetium Lu 177 dotatate 46Magnetic Resonance Spectroscopy 33pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 24lanreotide 23cabozantinib 22pasireotide 21gallium Ga 68 dotatate 21lenvatinib 20Etoposide 19Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18Sunitinib 17Bevacizumab 16trametinib 15dabrafenib 15Doxorubicin 143-Iodobenzylguanidine 14surufatinib 13Sorafenib 13Ipilimumab 13Thyrotropin Alfa 12Injections 12Positron Emission Tomography Computed Tomography 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Rosiglitazone × Endocrine × Clear all
NCT00616642 2020-08-14

Rosiglitazone in Treating Patients With Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
1 enrolled 4 charts
CNSEndocrine

Pituitary Neoplasms, Central Nervous System Neoplasms

NCT00612066 2020-08-06

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
2 enrolled 5 charts
Endocrine

Pituitary ACTH Hypersecretion

NCT03309319 2017-10-13

A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas

Huashan Hospital

Phase NA Unknown
24 enrolled
Endocrine

Pituitary Neoplasms

NCT00098852 2014-01-06

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
25 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT01100619 2013-09-19

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Exelixis

Phase 1 Completed
40 enrolled
EndocrineGenitourinaryHead & Neck

Thyroid Cancer, Papillary, Carcinoma, Renal Cell, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡